Search

Dragan Cicic

from Brooklyn, NY
Age ~61
Get Report
Also known as:
Dragam Cicic, Drogan Cicic, Cicic Dragan
Phone and address:
393 17Th St, Brooklyn, NY 11215
(718) 369-5034
Related to:
Maja Lekovic Cicic, 64
Connected to:
Gerald J Cicierega, 94Veronica E Cicilian, 42Nicole C Cicillini, 35Stephen E Cicilline, 83Daniel H Cicio, 65Vincent V Cicio, 83Virginia L Cicio, 37Bernadette M Cicione, 67Dominick A Cicione, 50Matthew L Cicione, 66

Dragan Cicic Phones & Addresses

  • 393 17Th St, Brooklyn, NY 11215 (718) 369-5034 (718) 369-7089
  • 393 17Th St #1A, Brooklyn, NY 11215 (718) 369-5034
  • 87 Sherman St, Brooklyn, NY 11218 (718) 369-5034 (718) 369-7089
  • 68 Drexelbrook Dr, Drexel Hill, PA 19026 (610) 623-5483
  • 6817 Drexelbrook Dr #17, Drexel Hill, PA 19026 (610) 623-5483
  • 12 Ellery St, Cambridge, MA 02138 (617) 441-5301
  • 12 Ellery St #504, Cambridge, MA 02138 (617) 441-5301
  • 87 Sherman St, Brooklyn, NY 11218 (718) 369-5034

Work

Position: Production Occupations

Education

Degree: Associate degree or higher

Resumes

Resumes

Dragan Cicic Photo 1

Project Director

View page
Location:
393 17Th St, Brooklyn, NY 11215
Industry:
Biotechnology
Work:
Qed Technologies
Project Director
Dragan Cicic Photo 2

Medical Director

View page
Location:
New York, NY
Industry:
Biotechnology
Work:
Qed Technologies May 2002 - Dec 2005
Project Director
Actinium Pharmaceuticals, Inc. May 2002 - Dec 2005
Medical Director
Education:
The Wharton School 1998 - 2000
Master of Business Administration, Masters, Finance University of Belgrade
Doctor of Medicine, Doctorates
Skills:
Pharmaceutical Industry
Oncology
Clinical Development
Biotechnology
Biopharmaceuticals
Cro
Drug Development
Clinical Trials
Start Ups
Regulatory Affairs
Clinical Research
Drug Discovery
Regulatory Submissions

Business Records

Name / Title
Company / Classification
Phones & Addresses
Dragan Cicic
Chief Executive Officer, Director
Actinium Pharmaceuticals, Inc
Cancer Research · Noncommercial Research Organization Commercial Physical Research
391 Lafayette St, Newark, NJ 07105
379 Thornall, Newark, NJ 07105

Publications

Us Patents

Low Dose Antibody-Based Methods For Treating Hematologic Malignancies

View page
US Patent:
20220251196, Aug 11, 2022
Filed:
Feb 24, 2022
Appl. No.:
17/679213
Inventors:
- New York NY, US
Dragan Cicic - Brooklyn NY, US
Assignee:
Actinium Phamaceuticals, Inc. - New York NY
International Classification:
C07K 16/28
A61K 47/68
A61P 35/02
A61K 51/10
Abstract:
This invention provides a method for treating a subject afflicted with a hematologic malignancy comprising administering to the subject an agent targeting a hematologic malignancy-associated antigen, wherein the subject has a low peripheral cancerous cell burden. This invention also provides a method for treating a subject afflicted with a hematologic malignancy and having a high peripheral cancerous cell burden, comprising (i) medically lowering the subject's peripheral cancerous cell burden, and (ii) while the subject's peripheral cancerous cell burden is still low, administering to the subject an agent targeting a hematologic malignancy-associated antigen. Particularly envisioned are the subject methods for treating acute myeloid leukemia using an anti-CD33 antibody labeled with an alpha-emitting isotope, such as Ac-HuM195.

Method For Treating Cancer Using A Bcl-2 Inhibitor In Conjunction With An Alpha-Emitting Radioimmunotherapeutic

View page
US Patent:
20200383974, Dec 10, 2020
Filed:
Apr 26, 2018
Appl. No.:
16/607168
Inventors:
- New York NY, US
Dragan Cicic - Brooklyn NY, US
Assignee:
Actinium Pharmaceuticals, Inc. - New York NY
International Classification:
A61K 31/496
C07K 16/28
A61K 51/10
A61P 35/02
Abstract:
This invention provides a method for treating a subject afflicted with cancer, comprising administering to the subject (i) a BCL-2 inhibitor in conjunction with (ii) an alpha-emitting isotope-labeled agent that targets cancer cells in the subject, wherein the amounts of the BCL-2 inhibitor and labeled agent, when administered in conjunction with one another, are therapeutically effective. This invention also provides a method for inducing the death of a cancer cell, comprising contacting the cell with (i) a BCL-2 inhibitor in conjunction with (ii) an alpha-emitting isotope-labeled agent that targets the cancer cell, wherein the amounts of BCL-2 inhibitor and labeled agent, when concurrently contacted with the cell, are effective to induce the cell's death.

Low Dose Antibody-Based Methods For Treating Hematologic Malignancies

View page
US Patent:
20190263903, Aug 29, 2019
Filed:
May 25, 2017
Appl. No.:
16/300672
Inventors:
- New York NY, US
Dragan CICIC - Brooklyn NY, US
Assignee:
Actinium Pharmaceuticals, Inc. - New York NY
International Classification:
C07K 16/28
A61P 35/02
A61K 47/68
A61K 51/10
Abstract:
This invention provides a method for treating a subject afflicted with a hematologic malignancy comprising administering to the subject an agent targeting a hematologic malignancy-associated antigen, wherein the subject has a low peripheral cancerous cell burden. This invention also provides a method for treating a subject afflicted with a hematologic malignancy and having a high peripheral cancerous cell burden, comprising (i) medically lowering the subject's peripheral cancerous cell burden, and (ii) while the subject's peripheral cancerous cell burden is still low, administering to the subject an agent targeting a hematologic malignancy-associated antigen. Particularly envisioned are the subject methods for treating acute myeloid leukemia using an anti-CD33 antibody labeled with an alpha-emitting isotope, such as Ac-HuM195.
Control profile
Dragan Cicic from Brooklyn, NY, age ~61 Get Report